A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma

Exclusion Criteria

• •1. Concomitant respiratory diseases that, as determined by investigators, may affect the evaluation of therapeutic effects or safety of the investigational product;
• •2. A participant who experiences a severe asthma exacerbation at any time from 4 weeks prior to the screening up to and including the baseline;
• •3. Allergic to any component of the investigational product or intolerant to basis treatment;
• •4. Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to;
• •5. Other reasons the investigators believe that the participants are not suitable to enrolled in this study.